CN106215118A - 抗肿瘤的保健制剂及其制备方法 - Google Patents
抗肿瘤的保健制剂及其制备方法 Download PDFInfo
- Publication number
- CN106215118A CN106215118A CN201610745179.2A CN201610745179A CN106215118A CN 106215118 A CN106215118 A CN 106215118A CN 201610745179 A CN201610745179 A CN 201610745179A CN 106215118 A CN106215118 A CN 106215118A
- Authority
- CN
- China
- Prior art keywords
- preparation
- radix
- poria
- superfine powder
- concentrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 101
- 230000036541 health Effects 0.000 title claims abstract description 52
- 230000000118 anti-neoplastic effect Effects 0.000 title claims description 36
- 241000222336 Ganoderma Species 0.000 claims abstract description 42
- 244000269722 Thea sinensis Species 0.000 claims abstract description 41
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 39
- 239000011669 selenium Substances 0.000 claims abstract description 39
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 38
- 239000009636 Huang Qi Substances 0.000 claims abstract description 35
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 30
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 230000033228 biological regulation Effects 0.000 claims abstract description 10
- 239000007787 solid Substances 0.000 claims abstract description 10
- 239000006188 syrup Substances 0.000 claims abstract description 7
- 235000020357 syrup Nutrition 0.000 claims abstract description 7
- 239000003826 tablet Substances 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 239000002671 adjuvant Substances 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims abstract description 5
- 239000006187 pill Substances 0.000 claims abstract description 5
- 238000001816 cooling Methods 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 69
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000000469 ethanolic extract Substances 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000004278 EU approved seasoning Substances 0.000 claims description 4
- 235000011194 food seasoning agent Nutrition 0.000 claims description 4
- 239000004576 sand Substances 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 3
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 208000013219 diaphoresis Diseases 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000010985 leather Substances 0.000 claims description 2
- 230000007480 spreading Effects 0.000 claims description 2
- 238000003892 spreading Methods 0.000 claims description 2
- 239000010902 straw Substances 0.000 claims description 2
- 241000218628 Ginkgo Species 0.000 claims 5
- 244000283207 Indigofera tinctoria Species 0.000 claims 1
- 241000497005 Ixophorus unisetus Species 0.000 claims 1
- 241000209140 Triticum Species 0.000 claims 1
- 230000006837 decompression Effects 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 58
- 206010028980 Neoplasm Diseases 0.000 abstract description 57
- 210000004369 blood Anatomy 0.000 abstract description 46
- 239000008280 blood Substances 0.000 abstract description 45
- 210000000952 spleen Anatomy 0.000 abstract description 33
- 230000000259 anti-tumor effect Effects 0.000 abstract description 29
- 244000194101 Ginkgo biloba Species 0.000 abstract description 26
- 231100000614 poison Toxicity 0.000 abstract description 18
- 210000003734 kidney Anatomy 0.000 abstract description 13
- 210000002216 heart Anatomy 0.000 abstract description 12
- 239000002574 poison Substances 0.000 abstract description 11
- 230000001717 pathogenic effect Effects 0.000 abstract description 10
- 230000036737 immune function Effects 0.000 abstract description 6
- 244000052769 pathogen Species 0.000 abstract description 6
- 230000023597 hemostasis Effects 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 abstract description 3
- 206010052428 Wound Diseases 0.000 abstract description 2
- 230000035876 healing Effects 0.000 abstract description 2
- 210000000056 organ Anatomy 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 62
- 235000013616 tea Nutrition 0.000 description 38
- 201000011510 cancer Diseases 0.000 description 27
- 210000004072 lung Anatomy 0.000 description 20
- 229940079593 drug Drugs 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 230000001737 promoting effect Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 239000000284 extract Substances 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 206010011224 Cough Diseases 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 13
- 235000009508 confectionery Nutrition 0.000 description 13
- 230000007812 deficiency Effects 0.000 description 13
- 230000036039 immunity Effects 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 210000000582 semen Anatomy 0.000 description 13
- 208000004880 Polyuria Diseases 0.000 description 12
- 230000001093 anti-cancer Effects 0.000 description 12
- 230000035619 diuresis Effects 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 11
- 206010030113 Oedema Diseases 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 10
- 229960004949 glycyrrhizic acid Drugs 0.000 description 10
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 10
- 235000019410 glycyrrhizin Nutrition 0.000 description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 239000004378 Glycyrrhizin Substances 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 208000006673 asthma Diseases 0.000 description 9
- 210000001124 body fluid Anatomy 0.000 description 9
- 239000010839 body fluid Substances 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 240000005373 Panax quinquefolius Species 0.000 description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 239000003440 toxic substance Substances 0.000 description 7
- 244000025254 Cannabis sativa Species 0.000 description 6
- 206010033557 Palpitations Diseases 0.000 description 6
- 239000003570 air Substances 0.000 description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 238000002481 ethanol extraction Methods 0.000 description 6
- -1 reclaim Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 5
- 208000033809 Suppuration Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 201000008275 breast carcinoma Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 201000005619 esophageal carcinoma Diseases 0.000 description 5
- 239000003172 expectorant agent Substances 0.000 description 5
- 230000003419 expectorant effect Effects 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 235000008434 ginseng Nutrition 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- QRMPRVXWPCLVNI-YYFQZIEXSA-N Curcumol Chemical compound C1C(=C)[C@@H]2CC[C@H](C)[C@@]22C[C@@H](C(C)C)[C@]1(O)O2 QRMPRVXWPCLVNI-YYFQZIEXSA-N 0.000 description 4
- 240000008397 Ganoderma lucidum Species 0.000 description 4
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- WBNQDOYYEUMPFS-UHFFFAOYSA-N N-nitrosodiethylamine Chemical compound CCN(CC)N=O WBNQDOYYEUMPFS-UHFFFAOYSA-N 0.000 description 4
- 235000003434 Sesamum indicum Nutrition 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000000711 cancerogenic effect Effects 0.000 description 4
- 231100000315 carcinogenic Toxicity 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000003405 preventing effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 239000011800 void material Substances 0.000 description 4
- 239000002023 wood Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 3
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 3
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 244000040738 Sesamum orientale Species 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000012886 Vertigo Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 231100000889 vertigo Toxicity 0.000 description 3
- 201000001862 viral hepatitis Diseases 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 241001278836 Agrimonia pilosa Species 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282461 Canis lupus Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- 241000219104 Cucurbitaceae Species 0.000 description 2
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 240000004343 Indigofera suffruticosa Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 206010030124 Oedema peripheral Diseases 0.000 description 2
- 206010030302 Oliguria Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002115 aflatoxin B1 Substances 0.000 description 2
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 2
- 229930020125 aflatoxin-B1 Natural products 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000007368 endocrine function Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- TYFJTEPDESMEHE-HNNXBMFYSA-N (3s)-6,8-dihydroxy-3-[2-(4-methoxyphenyl)ethyl]-3,4-dihydroisochromen-1-one Chemical compound C1=CC(OC)=CC=C1CC[C@@H]1OC(=O)C2=C(O)C=C(O)C=C2C1 TYFJTEPDESMEHE-HNNXBMFYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 235000000641 Agrimonia pilosa Nutrition 0.000 description 1
- NQGCBDWQKDAGTK-RYZVSIALSA-N Agrimophol Chemical compound CC1=C(OC)C(C(=O)CCC)=C(O)C(C[C@]2(C)C(C(C(=O)[C@H](C)CC)=C(O)C(C)=C2O)=O)=C1O NQGCBDWQKDAGTK-RYZVSIALSA-N 0.000 description 1
- NQGCBDWQKDAGTK-QDXKXIGTSA-N Agrimophol Natural products O=C(CCC)c1c(OC)c(C)c(O)c(C[C@]2(C)C(=O)C(C(=O)[C@H](CC)C)=C(O)C(C)=C2O)c1O NQGCBDWQKDAGTK-QDXKXIGTSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000722818 Aralia Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 235000004360 Dioscorea zingiberensis Nutrition 0.000 description 1
- 241001678283 Dioscorea zingiberensis Species 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000380130 Ehrharta erecta Species 0.000 description 1
- 241001362421 Epimedium brevicornu Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241001646826 Isodon rubescens Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- HLDYLAJAWSKPFZ-UHFFFAOYSA-N Monoglucuronylglycyrrhetinic acid Chemical compound C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1O HLDYLAJAWSKPFZ-UHFFFAOYSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 241000219289 Silene Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 241001563853 Sphallerocarpus gracilis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010043966 Tongue neoplasm malignant stage unspecified Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- XYUNNDAEUQFHGV-UHFFFAOYSA-N [Se].[Se] Chemical compound [Se].[Se] XYUNNDAEUQFHGV-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- TYFJTEPDESMEHE-UHFFFAOYSA-N agrimonolide Natural products C1=CC(OC)=CC=C1CCC1OC(=O)C2=C(O)C=C(O)C=C2C1 TYFJTEPDESMEHE-UHFFFAOYSA-N 0.000 description 1
- VQKFNUFAXTZWDK-UHFFFAOYSA-N alpha-methylfuran Natural products CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 229930182483 coumarin glycoside Natural products 0.000 description 1
- 150000008140 coumarin glycosides Chemical class 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229930187479 gypenoside Natural products 0.000 description 1
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 1
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000008929 jingui shenqi Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 108010086652 phytohemagglutinin-P Proteins 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 1
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及保健制剂领域,特别是一种抑制肿瘤的保健制剂及其制备方法,其特征在于:其原料组成和重量份数为:富硒茶15~30、仙鹤草10~15、绞股蓝5~10、灵芝3~8、西洋参3~5、意苡仁15~25、制茯苓10~20、白术5~10、黄芪10~20、淫羊藿5~10、银杏叶5~10、姜黄3~8、甘草4~8,加入符合卫生标准的辅料或溶液,制成保健制剂的固体制剂或液体制剂;所述的固体制剂是胶囊剂、片剂、丸剂或颗粒剂;所述的液体制剂是口服液或糖浆剂或是袋泡茶,具有凉血止血、养伤退肿、清解积毒、抗肿瘤、强心益肾、健脾祛湿、调节五脏六腑,提高人体的免疫功能及扶正驱邪作用。
Description
技术领域
本发明涉及保健制剂领域,特别是一种抑制肿瘤的保健制剂及其制备方法。
背景技术
肿瘤(Tumor) 是机体在各种致癌因素作用下,局部组织的某一个细胞在基因水平上失去对其生长的正常调控,导致其克隆性异常增生而形成的异常病变而产生的,20世纪后期近30年以来癌症发病一直呈上升的趋势,据世界卫生组织(WHO)报告,1990年全球癌症新发病例数约807万,比1975年的517万增加了37.4%,而1997年全球的癌症死亡数约620万,并且按目前的趋势预测,至2020年随着世界人口达80亿,将有2000万新发癌症病例,其中死亡人数将达1200万,且其中绝大部分将发生在发展中国家;几十年来,由于生态环境的不断恶化、艾滋病等疾病的传播,恶性肿瘤的发病率呈上升趋势,并成为继心血管疾病之后的第二大致死病因。目前,对肿瘤的治疗手段有显著进步,但对危害人类生命健康最严重的、占恶性肿瘤90%以上的实体瘤的治疗尚未能达到令人满意的效果。
肿瘤是机体组织细胞,在不同致癌因素长期作用下,发生一系列过度的,不协调的增生和异常分化而形成的病变,即使致癌因素停止作用后,仍然继续过度生长。其外形常表现为肿块,一般为良性与恶性两种。由于肿瘤的病因繁多,病种不一,临床表现多端,所以病理变化也是非常复杂的,并非孤立和单一的。近代中医学认为,恶性肿瘤(癌症)的病机大约有阴阳失调、气滞血痴、痔结湿聚,热毒内蕴、气血亏虚等引起,特别是在工业文明发达的今天,人们时刻面对各种环境压力、环境污染,水、空气以及化肥、农药、汽车尾气,食品添加剂、饮食不洁和经常食用腌制熏烤的食品、吸烟、饮酒、噪音干扰及大气放射物质等因素影响。这些各种外源性毒素通过不同途径进入人的机体、危害健康,而机体新陈代谢功能的紊乱,极其容易把代谢中产生的各种废物堆积停滞在代谢管道中,堵塞正常排泄通道,构成内源性毒素,诱发人体产生各种病状。最终会造成机体的各种功能紊乱,如内分泌失调,脂肪代谢失调、免疫系统功能下降等,导致肿瘤的发生。因此,肿瘤学一直是医学研究的重点,寻找有效的抗肿瘤药物与方法,彻底攻克肿瘤是世界医学界的重要研究课题。研究表明许多中药具有抗肿瘤作用,尤其是复方,具有多种作用成分和通过多种作用途径产生抗肿瘤作用。近年来一些医学机构和医务工作者发表了较多利用中草药治疗抑制肿瘤的公开文献报道,例如:
1、中国专利,申请号:02131252.4,申请日:2002.09.19,名称:一种治疗恶性肿瘤的中药制剂及其制备方法,申请人:于天德,发明人:于天德 ,摘要:一种治疗恶性肿瘤的中药制剂及其制备方法,该中药制剂是以白花蛇舌草、肿节风、半枝莲、延胡索、三棱、莪术、丹参、人参、黄芪、灵芝、鸡血藤、生地、枸杞子、天花粉、蒲公英、山豆根、苦参、甘草为主要原料,由以下步骤制备而成的:原料准备,中药制剂制备,成品加工、包装、检验。根据临床使用本发明治疗癌症药物的结果表明:该药对各种肿瘤皆有很好的疗效。服药后数日即见肿瘤患者瘤体明显缩小。对晚期癌疼有持久性止疼效果。各种癌症患者服药后均无不反应和毒副作用,均能达到缓解症状延长寿命的效果。
2、中国专利,申请号:200910019337.6,申请日:2009.10.15,名称:一种抗肿瘤的中药组合物,公开号:CN101664536,公开日:2010.03.10,申请人:赵金忠,发明人:赵金忠;赵明阳,摘要:一种抗肿瘤的中药组合物。其主要由柴胡、郁金、香附、川芎、当归、丹参、牡丹皮、赤芍、人参、白术、黄芪、生地黄、半枝莲、白花蛇舌草、蒲公英等原料药制成。它可以单独使用治疗肿瘤,也可以与手术、放疗、化疗同时使用,其特点是见效快,疗效可靠,没有发现有明显副作用,既可以在短期内控制肿瘤的生长,消除肿瘤,同时还可以明显的增强人体体质,提高其自身抗病修复能力。是一种比手术、化疗、放疗更有效果、而且没有副作用的理想抗肿瘤药物。
3、中国专利,申请号:200410013488.8,申请日:2004.07.19,名称:一种治疗癌症的中药制剂及其制备方法,公开号:CN1596936,公开日:2005.03.23,申请人:邢乐道,地址:湖北省团风县人民医院药科楼,发明人:邢乐道;黄硕彦,摘要:一种治疗癌症的中药制剂及其制备方法,涉及一种治疗癌症,包括脑癌,胰腺癌等的中药制剂及其制备方法。中药制剂由番荔枝总内酯、白蚤休提取物、石见穿提取物、白花蛇舌草提取物、半枝莲提取物、商陆提取物、冬凌草提取物、虎杖提取物、仙鹤草提取物、蓖麻子、桃仁提取物、姜黄提取物等经粉碎,用二氧化碳作溶剂低温萃取,回收、浓缩、分离出有效成分,混合,经二氧化碳喷粉造粒,包埋得产品。该发明通过现代科学工艺将天然药物番荔枝总内酯与中药、中药提取物相结合,运用了纳米包埋技术,提高了疗效。它能取代化疗药物,能使恶性肿瘤瘤体缩小或消失,防止肿瘤的复发和转移,能镇痛、毒副作用小,能延长癌症患者的生存期。
4、中国专利,增强人体免疫功能的药物,申请号:200510020732.8,申请人:潘文祥,摘要:该发明提供了一种增强人体免疫功能的药物。按重量份由冬虫夏草8~20,雪莲花3~15,鹿茸0.2~2,灵芝草10~150,党参10~150,茯苓8~150,白术6~120,甘草3~50,当归10~150,川芎10~150,巴戟天10~150,淫羊藿10~150,知母10-150,黄柏10-150,三七10-200,水蛭10-200,黄芪10-200,丹参10-200,赤芍10-150,仙茅10-200原料组成。
上述公开文献报道的中药能够从中医的角度进行治疗,在抑制肿瘤方面有一定的效果。但是有的组方较复杂,有的仅仅在试验阶段,有待于临床验证。
发明内容
本发明的目的是提供一种抗肿瘤的保健制剂,他在广西民间医药的基础上,加以补充和整理,挖掘并开发出一种具有凉血止血、养伤退肿、清解积毒、抗肿瘤、强心益肾、健脾祛湿、调节五脏六腑,提高人体的免疫功能及扶正驱邪作用保健制剂及其制备方法。
广西是壮族聚居的地区,壮族先民在长期的生活生产实践和同疾病斗争的过程中,积累了丰富的运用本地草药资源治疗肿瘤的经验。近年来,在社会各界的共同努力下,壮医药研究取得了显著性进展。壮医药治疗肿瘤的研究也取得了可喜的进步。多种壮药提取物以及壮药组成的独特方剂、复方成药在防治肿瘤的临床和实验研究中取得良好的效果。本发明人经过多年的深入了解和研究,也总结到一种能够抑制肿瘤的中药制剂及其制备方法。
本发明所述的一种抗肿瘤的保健制剂,其原料组成和重量份数为:富硒茶15~30、仙鹤草10~15、绞股蓝5~10、灵芝3~8、西洋参3~5、意苡仁15~25、制茯苓10~20、白术5~10、黄芪10~20、淫羊藿5~10、银杏叶5~10、姜黄3~8、甘草4~8。
以上所述的抗肿瘤的保健制剂,加入天然的符合药食同源标准的辅料或溶液,制成保健制剂的固体制剂或液体制剂;所述的固体制剂是胶囊剂、片剂、丸剂或颗粒剂;所述的液体制剂是口服液或糖浆剂。
本发明所述的抗肿瘤的保健制剂,还可以制成袋泡茶。
以上所述的抗肿瘤的保健制剂的制备方法,固体制剂或液体制剂制备过程包括以下步骤:
(1)将灵芝原料用清水洗净,切成1~3cm小块,100~120℃热风烘干至水分低于5%,用超微粉碎机粉碎,过500目筛,得到灵芝超微粉,包装备用;
(2)将西洋参切成1~3cm小块,100~120℃热风烘干至水分低于5%,用超微粉碎机粉碎,过500目筛,得到西洋参超微粉,包装备用;
(3)将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草干燥,分别打成细粉,备用;
(4)接种后三年的茯苓采挖,洗净,用麦草铺在底部,将茯苓逐层铺叠,最上盖以厚麻袋,使其发汗,析出水分,取出,将水珠擦去,摊放阴凉处,待表面干燥后再发汗,如此反复3-4次至表面皱缩,皮色变为褐色,再置阴凉处晾至半干,分部切制,阴干;使用前将茯苓浸泡,洗净除去杂质,切片,用水蒸气蒸30分钟,然后用武火将细沙炒热,再将茯苓片倒入,炒成微黄色时,取出,筛去细沙,摊凉,打成超微粉,得到制茯苓,备用;
以上所述的抗肿瘤的保健制剂,固体制剂制备是将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草细粉合并,加8倍量体积浓度70-90%的乙醇提取二次,每次2h,滤过,合并滤液,放置过夜,回收乙醇并浓缩至60℃相对密度为1.12-1.15的浓液,得乙醇提取液;再将药渣加入5倍重量水,煎煮2次,每次0.5小时,滤过,合并煎液,浓缩至60℃相对密度为1.05,合并乙醇提取液,回收乙醇并浓缩至60℃相对密度为1.12-1.15,与上述醇提浓缩液合并,继续浓缩至60℃相对密度为1.25-1.30的稠膏,减压干燥,粉碎成细粉,加入灵芝超微粉、西洋参超微粉、茯苓超微粉及辅料,制成片剂、颗粒剂、胶囊和丸剂,即得固体制剂。
以上所述的抗肿瘤的保健制剂,所述的液体制剂的制备方法是将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草细粉合并,加8倍量体积浓度70-90%的乙醇提取二次,每次2h,滤过,合并滤液,放置过夜,回收乙醇并浓缩至60℃相对密度为1.12-1.15的浓液,得乙醇提取液;再将药渣及灵芝超微粉、西洋参超微粉、茯苓超微粉加入10倍量水,煎煮三次,每次0.5小时,滤过,合并煎液,浓缩至60℃相对密度为1.05,调节含醇量至70%,冷藏过夜,回收乙醇并浓缩至60℃相对密度为1.12-1.15,与上述醇提浓缩液合并,再加适量糖浆和水,包装,高温灭菌,即得液体制剂。
所述的抗肿瘤的保健制剂袋泡茶的工艺是:将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草细粉合并,再将灵芝超微粉、西洋参超微粉、茯苓超微粉加入,包装,微波灭菌,即得袋泡茶。
据中药文献记载,以上所说的中药各成份的来源是:
富硒茶, 产地,陕西紫阳,湖北恩施,广西贵港,硒是一种化学元素,化学符号是Se,一种非金属。可以用作光敏材料、电解锰行业催化剂、动物体必需的营养元素和植物有益的营养元素等。硒元素含量远高于其它茶叶的茶被称为富硒茶。人体缺硒会造成多种疾病,最典型的是我国黑龙江克山县地方病—克山病,另外,大骨节病、癌症、心血管疾病、白内障、胞囊纤维变性、高血压、甲状腺肿大、免疫缺失、淋巴母细胞性贫血、视网膜斑点退化、溃疡性结肠炎以及人体的衰老都与人体缺硒有着直接的联系,硒能提高人体免疫,促进淋巴细胞的增殖及抗体和免疫球蛋白的合成。硒对结肠癌、皮肤癌、肝癌、乳腺癌等多种癌症具有明显的抑制和防护的作用,其在机体内的中间代谢产物甲基烯醇具有较强的抗癌活性。茶含有机化合物450多种、无机矿物质15种以上,这些成分大部分都具有保健、防病的功效。绿茶所含的成分—茶多酚及咖啡碱,两者所产生的综合作用,除了起到提神、养神之效,更具备提高人体免疫能力和抗癌的功效。特别是自然种植的富硒茶,而且是有机硒,比粮油中的硒更易被人吸收。
仙鹤草,拉丁文名:Agrimonia pilosa Ledeb,别名脱力草、瓜香草、老牛筋、狼芽草。来源为蔷薇科植物龙芽草Agrimonia pilosa Ledeb的地上部分。全草夏、秋季采收。芽冬、春季新株萌发前采收。功效与作用:止血,促进血液凝固,强心,调整心率,大量服用能使心搏徐缓。据报道,每日用仙鹤草提取物500微克,连续6天分别注入(1毫升)癌细胞培养液和正常细胞培养液中,能完全消灭癌细胞,但正常细胞仍继续繁殖,不受损害。粗制浸膏能促进动物血液凝固。家兔静脉注射仙鹤草素后可大大缩短其血凝时间,增加血小板,促进血小板的生成并能增加血钙;实验性狗股动脉出血,局部应用粉剂并加压迫有一定的止血作用。仙鹤草素对小鼠、大鼠、家兔均有调整心率,使已疲劳的骨骼肌兴奋,增加细胞的抵抗力及降低血糖等作用;仙鹤草内酯能降低离体兔肠的收缩幅度及张力,也能抑制在体小鼠肠的蠕动。
绞股蓝,拉丁文名:Gynostemma pentaphyllum (Thunb.) Makino,又称:天堂草、福音草、超人参、公罗锅底、遍地生根、七叶胆、五叶参和七叶参等,葫芦科、绞股蓝属草质攀援植物;茎细弱,具分枝,具纵棱及槽,无毛或疏被短柔毛。绞股蓝喜阴湿温和的气候,多野生在林下、小溪边等荫蔽处,多年生攀援草本。在中国主要分布在陕西平利、甘肃康县、湖南、湖北,云南、广西等省,号称“南方人参”,生长在广西的绞股蓝药用含量比较高,民间称其为神奇的“不老长寿药草”,1986年,国家科委在“星火计划”中,把绞股蓝列为待开发的“名贵中药材”之首位,2002年3月5日国家卫生部将其列入保健品名单。药材基源:为葫芦科植物绞股蓝的全草。绞股蓝主要有效成份是绞股蓝皂甙、绞股蓝糖甙(多糖)、水溶性氨基酸、黄酮类、多种维生素、微量元素、矿物质等。性味:味苦;微甘;性凉。归经:归肺;脾;肾经。功效:益气健脾,化痰止咳,清热解毒。主治体虚乏力;虚劳失精;白细胞减少症;高脂血症;病毒性肝炎;慢性胃肠炎;慢性气管炎。本种入药,有消炎解毒、止咳祛痰的功效。用绞股蓝与灵芝搭配煮水或泡茶喝,可以降血脂,调血压防治血栓,防治心血管疾患,调节血糖,促睡眠,缓衰老,防抗癌,提高免疫力,调节人体生理机能。
灵芝,拉丁文名:Ganoderma Lucidum Karst,又称林中灵、琼珍,是多孔菌科真菌灵芝的子实体。具有补气安神、止咳平喘的功效,用于眩晕不眠、心悸气短、神经衰弱、虚劳咳喘,延年益寿的功效。《本草经集注》曰:此六芝皆仙草之类,俗所稀见,族种甚多,形色环异,并载《芝草图》中。今俗所用紫芝,此是朽树木株上所生,状如木檽。《纲目》把历代有关芝类的记载加以引证,并提出了自己的见解,曰:芝类甚多,亦有花实者,本草惟以六芝标名,然其种属不可不识。《神农本草经》:“赤芝,味苦平。主胸中结,益心气,补中,增慧智,不忘。久食,轻身不老,延年神仙。一名丹芝。灵芝药用在我国已有2000多年的历史,被历代医药家视为滋补强壮、扶正固本的神奇珍品。药理研究证明,灵芝有多方面的生物活性。主含氨基酸、多肽、蛋白质、真菌溶菌酶(fungal lysozyme),以及糖类(还原糖和多糖)、麦角甾醇、三萜类、香豆精甙、挥发油、硬脂酸、苯甲酸、生物碱、维生素B2及C等;孢子还含甘露醇、海藻糖(trehalose)。灵芝对中枢神经系统、心血管系统、呼吸系统、内分泌功能、保肝、抗氧化、延缓衰老、抗炎作用,抗肿瘤等都起到很好的治疗作用,尤其是灵芝提取物在体外具有明显的抗肿瘤作用,保护放化疗损伤,免疫调节,并对放射线和化疗药引起的正常人细胞的损伤具有保护作用。
西洋参,拉丁文名:Panax quinquefolius,五加科人参属,多年生草木植物,别名花旗参、洋参、西洋人参、American ginseng,味苦、微甘,归心、肺、肾经,具有补肺降火、养胃生津之功效。功能主治:补气养阴,清热生津。用于气虚阴亏,内热,咳喘痰血,虚热烦倦,生津止渴。益肺阴,清虚火,凉血滋阴,泻火解毒;能强化心肌及增强心脏之活动能力,强壮中枢神经,有镇静及解酒作用,增强记忆能力,对老人痴呆症有显著功效,能调节胰岛之分泌,对肝脏有调节毒素之分泌,能增强体力并对运动员具极大助益,抑制癌细胞生长,增加免疫功能。
意苡仁,拉丁文名:Semen Coicis,英文名:Coix Seed,又名薏仁、苡米、苡仁,土玉米,薏米、起实、薏珠子、草珠珠、回回米、米仁、六谷子。禾本科植物薏苡的干燥成熟种仁。《本草纲目》列为上品,是常用的中药,薏仁富含淀粉、蛋白质、多种维生素及人体所需的多种氨基酸,性味甘淡微寒,薏仁性凉,味甘、淡。有健脾渗湿,除痹止泻。薏米具有健脾利湿、清热排脓等功效,可用于治疗水肿、脚气、小便不利、湿痹拘挛、脾虚泄泻、健脾,渗湿,止泻,排脓,对心血管、抗肿瘤、增强免疫力和抗炎作用,薏苡仁油对细胞免疫、体液免疫有促进作用。
茯苓,拉丁文名:Poria cocos(Schw.)Wolf,为多孔菌科真菌茯苓,真菌的干燥菌核。《本草纲目》:茯苓气味淡而渗,其性上行,生津液,开腠理,滋水源而下降,利小便,故张洁古谓其属阳,浮而升,言其性也;东垣谓其为阳中之阴,降而下,言其功也。《本草衍义》:茯苓、茯神,行水之功多,益心脾不可阙也。《本草正》:能利窍去湿,利窍则开心益智,导浊生津;去湿则逐水燥脾,补中健胃;袪惊痫,厚肠脏,治痰之本,助药之降。性味:味甘、淡,性平。归经:归心、肺、脾、肾经。功效:利水渗湿,健脾,宁心。用于治疗水肿尿少,痰饮眩悸,脾虚食少,便溏泄泻,心神不安,惊悸失眠等症,尤其适用于治疗癌症,临床常用于治疗食管癌、胃癌、肝癌、鼻咽癌、舌癌、乳腺癌、膀胱癌、肺癌、溃疡性黑色素瘤等癌瘤中属脾虚湿盛、痰饮内停、湿热壅结者。
白术,拉丁文名:Atractylodes macrocephala。别名桴蓟,于术,冬白术,淅术,杨桴,吴术,片术、苍术等,属于菊科、苍术属多年生草本植物。喜凉爽气候,以根茎入药,具有多项药用功能。主要分布于四川、云南、贵州等山区湿地。《医学启源》记载:“除湿益燥,和中益气,温中,去脾胃中湿,除胃热,强脾胃,进饮食,安胎。”《神农本草经》:术。味苦温。主风寒湿痹死肌,痉疸,止汗,除热,消食,作煎饵。久服轻身延年,不饥。一名山蓟,生山谷。《长沙药解》:味甘、微苦,入足阳明胃、足太阴脾经。补中燥湿,止渴生津,最益脾精,大养胃气,降浊阴而进饮食,善止呕吐,升清阳而消水谷,能医泄利。性味归经,味苦,甘,性温。归脾、胃经。功能主治:健脾益气,燥湿利水,止汗,安胎。用于脾虚食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。白术具有利尿、降血糖、抗凝血、抗肿瘤、对胃肠平滑肌、抗菌、促进造血功能、促进蛋白质合成,尤其是对于治疗癌症,体外试验表明,白术挥发油中之中性油对食管癌细胞有明显抑制作用。10mcg/ml时,于24小时内可使癌细胞全部脱落。5mcg/ml时,可使大部分癌细胞脱落,残存的小片细胞或散在细胞呈核固缩,核仁模糊不清,泡质多空泡。白术挥发油50~100mg/kg腹腔注射对艾氏腹水癌有显着抑制作用。白术对methA肿瘤的中如活性比对照组明显增加,并显着增强MethA肿瘤的迟发性超敏反应,还促进植物血细胞凝集素-P和脂多糖诱导的幼若化反应。
黄芪,拉丁文名:Astragalus membranaceus (Fisch.) Bunge. 别称:棉芪,黄耆,独椹,蜀脂,百本,百药棉,黄参,血参,人衔等,多年生草本,高50-100厘米。主根肥厚,木质,常分枝,灰白色。茎直立,上部多分枝,有细棱,被白色柔毛。产于内蒙古、山西、甘肃、黑龙江等地。黄芪的药用迄今已有2000多年的历史,其有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌作用。性味:甘,微温。归经:归肺、脾、肝、肾经。用于治疗表虚自汗、阴虚盗汗、急性肾炎水肿、慢性肾炎水肿、脾肾虚、阳气虚弱、疮疡溃破、肺气虚证、气虚衰弱。
淫羊藿,拉丁文名:Epimedium brevicornu Maxim,别称:短角淫羊藿,又称仙灵脾。多年生草本植物,植株高20-60厘米,根状茎粗短,暗棕褐色,二回三出复叶基生和茎生,具长柄,小叶纸质或厚纸质,叶缘具刺齿,花白色或淡黄色,花期5-6月,果期6-8月。李时珍曰:淫羊藿味甘气香,性温不寒,能益精气,真阳不足宜之。主要价值淫羊藿味辛甘性温,走肝肾二经。为补命门、益精气、强筋骨、补肾壮阳之要药,有补肾壮阳,祛风除湿。治阳痿不举,小便淋沥,筋骨挛急,半身不遂,腰膝无力,风湿痹痛,四肢不仁作用。临床常用于治疗男子阳痿不举、滑精早泄、小便不禁以及女子不孕等症。现代研究表明,淫羊藿含淫羊藿甙、挥发油、蜡醇、植物甾醇、鞣质、维生素E等成分。能兴奋性机能,对动物有促进精液分泌作用。还有降压(引起周围血管舒张)、降血糖、利尿、镇咳祛痰以及维生素E样作用。药理实验研究表明,淫羊藿能增加心脑血管血流量,促进造血功能、免疫功能及骨代谢,具有抗衰老、抗肿瘤等功效。近代医学专家研究发现,淫羊藿能有效杀死乳腺癌细胞。
银杏叶,拉丁学名:Ginkgobiloba,别称:飞蛾叶、鸭脚子,二名法 Ginkgobiloba为银杏科植物银杏Ginkgo biloba L的干燥叶。秋季叶尚绿时采收,及时干燥。广西野生植物。其他地方一般为人工栽培。具有活血化瘀,通络止痛,敛肺平喘,化浊降脂的功效。用于瘀血阻络,胸痹心痛,中风偏瘫,肺虚咳喘,高脂血症。性味,甘、苦、涩,平。归经,归心、肺经。有活血化瘀,通络止痛,敛肺平喘,化浊降脂,抗癌等作用。用于瘀血阻络,胸痹心痛,中风偏瘫,肺虚咳喘,高脂血症。
姜黄,拉丁文名:Curcuma longa L,又名:郁金、宝鼎香、毫命、黄姜、黄丝等,属多年生草本植物,株高1~1.5m,根茎很发达,根粗壮,末端膨大呈块根;叶片长圆形或椭圆形,叶顶端短渐尖;苞片卵形或长圆形,淡绿色,顶端钝,花冠淡黄色;姜黄能行气破瘀,通经止痛。主治胸腹胀痛,肩臂痹痛,心痛难忍,产后血痛,疮癣初发,月经不调,闭经,跌打损伤。性味归经:辛苦,温。《唐本草》:味辛苦,大寒,无毒。《本草拾遗》:味辛,温,无毒。李杲:味苦甘辛,大寒,无毒。《东医宝鉴》:性热,味辛苦,无毒。入脾、肝经。《纲目》:入心、脾。《雷公炮制药性解》:入心、肺二经。《本草经疏》:入足太阴、厥阴。功能主治:破血,行气,通经,止痛。治心腹痞满胀痛,臂痛,症瘕,妇女血瘀经闭,产后瘀停腹痛,跌扑损伤,痈肿。具有降血脂作用:姜黄醇或醚提取物、姜黄素和挥发油,能降低肝胆固醇,纠正a-和B-脂蛋白比例失调;对降血浆甘油三酯的作用更为显著,能使血浆中甘油三酯降低至正常水平以下。抗肿瘤作用:姜黄醇提物能抑制癌细胞生长。在0.4mg/ml时能抑制中国仓鼠卵巢细胞生长,并对淋巴细胞和Dalton氏淋巴细胞具有细胞毒性作用,并能减少动物肿瘤的生长,其活性成分主要是姜黄素。在巴豆油促进下,7,12-二甲基苯蒽能诱发小鼠产生乳头癌,姜黄素可明显减少在此情况下乳头癌产生的机会,也能抑制由2O-甲基氯蒽诱导的肿瘤形成。姜黄素还能减少突变原致癌的可能性。
甘草,为豆科植物甘草,拉丁文名:Glycyrrhiza uralensis Fisch.、胀果甘草Glycyrrhiza inflate Bat.或光果甘草 Glycyrrhiza glabra L的干燥根及根茎,符合《中国药典》2005年版一部59-60页甘草项下有关规定。投料前洗净,烘干,切段。甘草:主要功效是和中缓急、润肺、解毒、调和诸药等,在多数方剂中都有应用,已经证明,甘草除具有清热解毒、抗惊厥、镇痛、镇咳祛痰止咳、脘腹等作用外,尚具有消炎、抗变态反应、抗溃疡、防治病毒性肝炎、抗癌、增强免疫性功能及抗艾滋病等作用。其化学成分是甘草甜素(主要是甘草酸的钾、钙盐,为甘草的甜味成分)、多种黄酮类化合物、多种三萜类化合物及香豆素、氨基酸、生物碱、雌激素和有机酸等。其中甘草甜素是其主要成分,实验研究表明,甘草甜素(GL)对黄曲霉素B1(AFB1)和二乙基亚硝胺(DEN)致大鼠肝癌前病变的发生均有明显的抑制作用, 并且GL在抑制DEN致肝癌前病变发生过程中对DNA损伤修复有明显的保护作用,GL使DNA修复功能接近正常水平, 从而降低了DEN的致癌性, 同时GL还可使肝癌前病变γ谷氨酸转肽酶阳性肝细胞增生灶减少。另外,甘草甜素经酶促水解得到的甘草次酸单葡糖醛酸甙(MGGR)对多种原因诱发的小鼠皮肤癌、肺癌有抑制作用。长期服用加入甘草甜素的饮用水可以抑制7,12-二甲基-苯并蒽(DMBA) 引起的小鼠皮癌。由于甘草酸一般是以钾盐或钙盐的形式存在于甘草中,其盐易溶于水,故对甘草采用水煎煮的提取方法。
本发明抗肿瘤的保健制剂的方解:
本发明抗肿瘤的保健制剂的验方主要由君药:以仙鹤草为主,由产于广西野生的银杏叶、绞股蓝和贵港产的富硒茶配上灵芝;臣药:西洋参、意苡仁、制茯苓、黄芪、淫羊藿;辅药:白术、姜黄、甘草等药物组成,具有散瘀肿、清热解毒、除湿毒、通调三道两路之作用。主要用于血瘀毒盛,气阴已虚之肝癌等恶性肿瘤的辅助治疗。方中仙鹤草可调火路,散瘀肿,清热毒,祛风毒,除湿毒。用于肿瘤,疮疡肿毒、消化道出血、腹痛、黄疸,跌打损伤等症;富硒茶的硒对结肠癌、皮肤癌、肝癌、乳腺癌等多种癌症具有明显的抑制和防护的作用,其在机体内的中间代谢产物甲基烯醇具有较强的抗癌活性。茶含有机化合物450多种、无机矿物质15种以上,这些成分大部分都具有保健、防病的功效。银杏叶有活血化瘀,通络止痛,敛肺平喘,化浊降脂。用于瘀血阻络,灵芝对中枢神经系统、心血管系统、呼吸系统、内分泌功能、保肝、抗氧化、延缓衰老、抗炎作用,抗肿瘤等都起到很好的治疗作用,尤其是灵芝提取物在体外具有明显的抗肿瘤作用,保护放化疗损伤,免疫调节,并对放射线和化疗药引起的正常人细胞的损伤具有保护作用;绞股蓝可益气健脾,清热解毒,主治体虚乏力,虚劳失精,白细胞减少症的功效,用绞股蓝与灵芝搭配煮水或泡茶喝,有保肝解毒、降血压、降血脂血糖的功效。防治心血管疾患,调节血糖,促睡眠,缓衰老,防抗癌,提高免疫力,调节人体生理机能;
散瘀解毒,通调道路共为主药、母药。制茯苓能利窍去湿,利窍则开心益智,导浊生津;去湿则逐水燥脾,补中健胃;袪惊痫,厚肠脏,治痰之本,助药之降。性味:味甘、淡,性平。归经:归心、肺、脾、肾经。功效:利水渗湿,健脾,宁心。主治:用于治疗水肿尿少,痰饮眩悸,脾虚食少,便溏泄泻,心神不安,惊悸失眠等症,尤其适用于治疗癌症;意苡仁味甘、淡具有健脾利湿、清热排脓等功效,对心血管、抗肿瘤、增强免疫力和抗炎作用,黄芪味苦甜,性热;益气固表、利水消肿、托毒排脓、敛疮生肌;用于气虚乏力,食少便溏,表虚自汗,气虚水肿,痈疽难溃,久溃不敛,血虚痿黄等,为方中公药。淫羊藿调气、解毒、补虚和通调三道两路之作用。对于血瘀毒盛,气阴已虚之肝癌等恶性肿瘤的辅助治疗,具有较好的临床效果。西洋参味苦、微甘,归心、肺、肾经,具有补肺降火、养胃生津之功效。功能主治:补气养阴,清热生津。用于气虚阴亏,内热,咳喘痰血,虚热烦倦,生津止渴。益肺阴,清虚火,凉血滋阴,泻火解毒;
辅以姜黄的抗肿瘤作用:姜黄醇提物能抑制癌细胞生长。在0.4mg/ml时能抑制中国仓鼠卵巢细胞生长,并对淋巴细胞和Dalton氏淋巴细胞具有细胞毒性作用,并能减少动物肿瘤的生长;白术健脾益气,燥湿利水,降血糖、抗凝血、抗肿瘤、对胃肠平滑肌、抗菌、促进造血功能、促进蛋白质合成,甘草清热解毒、镇痛、镇咳祛痰止咳、脘腹、消炎、抗变态反应、抗溃疡、防治病毒性肝炎、抗癌、增强免疫性功能并能和百药的作用。以上诸药合用,攻补兼施,消痛散结,标本兼顾,共奏滋阴养血、益气复脉、活血止痛和调节人体免疫系统功能,对抵抗肿瘤、保持排毒管道畅通,抑制癌细胞的生长均有作用。
本发明抗肿瘤的保健制剂具有传统壮族特色药物处方来源于壮族民间临床经验方。采用符合药食同源的天然的植物,根据其用药的特点,中草药治疗恶性肿瘤,是整体治疗与辨证施治相结合,也就是整体与局部相结合、既看到机体对病邪的抵御能力,又看到局部病变对机体的影响,在辨病与辨证的基础上,通过一些针对性强的特殊药物的配伍组方,恰到好处地进入机体,调节气血、阴阳、津液的平衡。药物分子经过物理反应和化学反应进入全身,有的吸附在细胞的表面、腐蚀围杀癌细胞,仙鹤草含有仙鹤草素、仙鹤草酚、仙鹤草内脂、仙鹤草醇、维生素c、K等具有抗菌、抗炎和抗肿瘤作用。配以富硒茶,补充人体所必须的徽量元素和氨基酸,增強体质。配以意苡仁利水渗湿、补益脾胃、增强免疫、抗肿瘤作用。配以山查,因为山查内黄酮类化合物牡荆素是一种抗癌作用较強的物质增强仙鹤草的抗肿瘤作用。配以绞股蓝,因为绞股蓝内含有皂甙类、黄酮类、磷脂类、多糖类、氨基酸、维生素等六大物质,具有抗癌防癌,抑制杀灭癌细胞作用,增強仙鹤草的抗肿瘤作用。辅以四君子汤(西洋参(四君子汤中原是人参,因西洋参具有益气生津作用)白术、茯苓、甘草)补气、健脾、养胃。补充人体正气不足,增强机体抵抗力,从而起到抗肿瘤作用。辅以黄芪增强四君子汤的补气功效,提高免疫力,辅以灵芝,增强抗癌抗肿瘤作用。仙鹤草辅以淫羊藿,补益真元虚亏,功效胜似金匮肾气丸。诸药配伍,能清解疫毒、消痰降浊、活血祛於、益气生津、补气养血,壮元固本,提高人体免疫力,全面调理人体的心、肝、脾、肺、肾生理功能,从而达到抗肿瘤的作用。通过制剂学、药效学、毒理学和质量控制等方面的深入研究,各种制剂安全、有效、质量稳定、可控。
具体实施方式
下面结合实施例对本发明抗肿瘤的保健制剂,作进一步说明。
一、制备实施例
实施例1
本发明的抗肿瘤的保健制剂,其原料组成和重量份数为:富硒茶15、仙鹤草10、绞股蓝5、灵芝3、西洋参3、意苡仁15、制茯苓10、白术5、黄芪10、淫羊藿5、银杏叶5、姜黄3、甘草4。
制备方法是将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草细粉合并,加8倍量体积浓度70%的乙醇提取2次,每次2h,滤过,合并滤液,放置过夜,回收乙醇并浓缩至60℃相对密度为1.15的浓液,得乙醇提取液;再将药渣加入5倍重量水,煎煮2次,每次0.5小时,滤过,合并煎液,浓缩至60℃相对密度为1.05,合并乙醇提取液,回收乙醇并浓缩至60℃相对密度为1.15,与上述醇提浓缩液合并,继续浓缩至60℃相对密度为1.30的稠膏,减压干燥,粉碎成细粉,加入灵芝超微粉、西洋参超微粉、茯苓超微粉及辅料,即制得片剂制剂。
实施例2
本发明的抗肿瘤的保健制剂,其原料组成和重量份数为:富硒茶30、仙鹤草15、绞股蓝10、灵芝8、西洋参5、意苡仁25、制茯苓20、白术10、黄芪20、淫羊藿10、银杏叶10、姜黄8、甘草8。
制备方法是将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草细粉合并,加8倍量体积浓度90%的乙醇提取2次,每次2h,滤过,合并滤液,放置过夜,回收乙醇并浓缩至60℃相对密度为1.12的浓液,得乙醇提取液;再将药渣加入5倍重量水,煎煮2次,每次0.5小时,滤过,合并煎液,浓缩至60℃相对密度为1.05,合并乙醇提取液,回收乙醇并浓缩至60℃相对密度为1.12,与上述醇提浓缩液合并,继续浓缩至60℃相对密度为1.25的稠膏,减压干燥,粉碎成细粉,加入灵芝超微粉、西洋参超微粉、茯苓超微粉及辅料,即制得颗粒剂制剂。
实施例3
本发明的抗肿瘤的保健制剂,其原料组成和重量份数为:富硒茶20、仙鹤草13、绞股蓝8、灵芝5、西洋参4、意苡仁23、制茯苓19、白术8、黄芪18、淫羊藿7、银杏叶9、姜黄5、甘草5。
制备方法是将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草细粉合并,加8倍量体积浓度80%的乙醇提取2次,每次2h,滤过,合并滤液,放置过夜,回收乙醇并浓缩至60℃相对密度为1.13的浓液,得乙醇提取液;再将药渣加入5倍重量水,煎煮2次,每次0.5小时,滤过,合并煎液,浓缩至60℃相对密度为1.05,合并乙醇提取液,回收乙醇并浓缩至60℃相对密度为1.14,与上述醇提浓缩液合并,继续浓缩至60℃相对密度为1.28的稠膏,减压干燥,粉碎成细粉,加入灵芝超微粉、西洋参超微粉、茯苓超微粉及辅料,即制得胶囊制剂。
实施例4
本发明的抗肿瘤的保健制剂,其原料组成和重量份数为:富硒茶25、仙鹤草12、绞股蓝7、灵芝4、西洋参3.5、意苡仁24、制茯苓18、白术6、黄芪16、淫羊藿9、银杏叶8、姜黄7、甘草6。
制备方法是将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草细粉合并,加8倍量体积浓度85%的乙醇提取二次,每次2h,滤过,合并滤液,放置过夜,回收乙醇并浓缩至60℃相对密度为1.14的浓液,得乙醇提取液;再将药渣加入5倍重量水,煎煮2次,每次0.5小时,滤过,合并煎液,浓缩至60℃相对密度为1.05,合并乙醇提取液,回收乙醇并浓缩至60℃相对密度为1.13,与上述醇提浓缩液合并,继续浓缩至60℃相对密度为1.26的稠膏,减压干燥,粉碎成细粉,加入灵芝超微粉、西洋参超微粉、茯苓超微粉及辅料,即制得丸剂制剂。
实施例5
本发明的抗肿瘤的保健制剂,其原料组成和重量份数为:富硒茶18、仙鹤草11、绞股蓝6、灵芝5、西洋参4.5、意苡仁22、制茯苓15、白术7、黄芪14、淫羊藿8、银杏叶7、姜黄4、甘草7。
本发明的抗肿瘤的保健制剂,其原料组成和重量份数为:是将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草细粉合并,加8倍量体积浓度75%的乙醇提取2次,每次2h,滤过,合并滤液,放置过夜,回收乙醇并浓缩至60℃相对密度为1.12的浓液,得乙醇提取液;再将药渣及灵芝超微粉、西洋参超微粉、茯苓超微粉加入10倍量水,煎煮三次,每次0.5小时,滤过,合并煎液,浓缩至60℃相对密度为1.05,调节含醇量至70%,冷藏过夜,回收乙醇并浓缩至60℃相对密度为1.15,与上述醇提浓缩液合并,再加适量糖浆和水,包装,高温灭菌,即制得液体制剂。
实施例6
本发明的抗肿瘤的保健制剂,其原料组成和重量份数为:富硒茶22、仙鹤草14、绞股蓝9、灵芝7、西洋参4、意苡仁18、制茯苓14、白术8、黄芪15、淫羊藿7、银杏叶6、姜黄5、甘草5。
本发明的抗肿瘤的保健制剂,其原料组成和重量份数为:是将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草细粉合并,加8倍量体积浓度78%的乙醇提取2次,每次2h,滤过,合并滤液,放置过夜,回收乙醇并浓缩至60℃相对密度为1.15的浓液,得乙醇提取液;再将药渣及灵芝超微粉、西洋参超微粉、茯苓超微粉加入10倍量水,煎煮三次,每次0.5小时,滤过,合并煎液,浓缩至60℃相对密度为1.05,调节含醇量至70%,冷藏过夜,回收乙醇并浓缩至60℃相对密度为1.12,与上述醇提浓缩液合并,再加适量糖浆和水,包装,高温灭菌,即制得液体制剂。
实施例7
本发明的抗肿瘤的保健制剂,其原料组成和重量份数为:富硒茶28、仙鹤草13、绞股蓝8、灵芝6、西洋参3.5、意苡仁20、制茯苓13、白术9、黄芪12、淫羊藿6、银杏叶8、姜黄6、甘草6。
制备方法是将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草细粉合并,再将灵芝超微粉、西洋参超微粉、茯苓超微粉加入,包装,微波灭菌,即得袋泡茶。
二、毒性试验:
取小白鼠40只,雌雄各20只,体重为15-20g,随机分为A,B,C,D四个组,每组10只,其中A组为正常喂食试验组,B组、 C组和D组除了正常喂食外,还注射了肝癌病菌,试验时,其中B组试验组喂食抗肝癌西药索拉非尼(多吉美),一次2gm,一日3次,C组试验组喂食公开文献报道的中国专利《一种治疗恶性肿瘤的中药制剂及其制备方法》,一次2g,一日3次;D组试验组采用本发明的抗肿瘤的保健制剂作为治疗实验组,正常喂给量为一次2g,每日早晚各一次,连续喂食一年,每天观察服药反应,结果是A组正常喂食试验组的小白鼠全部存活,并且行为无异常,无中毒症状,体型、粪便均无异常,全部体征良好;B组注射了肝癌病菌的小白鼠有两只小白鼠存活;B组注射了肝癌病菌有一只小白鼠存活;C组注射了肝癌病菌小白鼠全部存活,并且行为无异常,体型、粪便均无异常,检测体内肝癌病菌全部消失,以上实验表明本发明的抗肿瘤的保健制剂安全、无毒副作用,并对小白鼠的肝癌有很好的疗效。
三、临床观察:
收治年龄20-60岁的157例有乳腺肿瘤、肝癌、食道癌或直肠癌的患者进行重点观察,服用方式:每天1次,每次100g,1个月为1疗程,连服3-10个疗程,且服用期间,未出现不良反应,说明本发明所得产品安全无毒。观察结果显示本发明的抗肿瘤的保健制剂对上述症状的患者的病症完全痊愈119人,基本痊愈者32人,未痊愈者6人,痊愈者95%以上,且132人患者的体质、免疫力有所增强,精力充沛,面色润红,肠胃也有明显改善,有41人可以正常上班。
四、本发明抗肿瘤保健茶饮用案例:
1.乳腺肿瘤,陈x、女、36岁广西桂平市社步镇未河人。于2012年5月,检查为乳腺癌,到医院治疗十五天,情绪低落,口干舌燥,不思饮食。后经服用本发明的抗肿瘤的保健制剂2个月后,肿瘤减小,各症状消失,坚持服用两年。于2014年6月检查肿瘤消失,已正常工作。
2.肝癌。莫x、男56岁,广西桂平木乐广德塘人。因肝区疼痛,腹部肿胀,两足浮肿数月,2013年11月,经市人民院检查为中晚期肝癌,后服用本发明的抗肿瘤保健茶三个月疼痛减轻,腹部及足部浮肿消失,继续服用2年,恢复工作。
3.乳腺癌,节x、女43岁,广西桂平市马皮乡,左侧乳上方有肿瘤5Cmx6cm。2012年6月经医院检查为乳腺肿癌。因家庭经济困难拒绝到医院就医,后经服用本发明的抗肿瘤保健保8个月,肿瘤缩小三分一,继续服用一年半肿瘤全消,能正常工作。
4.肝癌,钟x,男38岁,广西桂平石嘴镇人,于2012年4月,因突然吐血到市人民医检查为原发性肝癌,经医院治疗三个月效果不佳,出现精神不振,不思饮食,身体消瘦,头晕很花,口干,四肢不温。后经服用本发明的抗肿保健茶两个月,各症状明显好转,继续服用一年各症状消失,能做一般的劳动。
5.食道癌,曾x、女,82岁,广西桂平木乐人,食道癌治疗半年,出现四肢不温,手足浮肿,汗出不止。后服用本发明人的抗肿瘤保健茶一个月,四肢不温、汗出不止症状消失,继续服用抗肿瘤茶1年,各症状消失。
6.鼻咽癌,何x,男,52岁,广西桂平市社坡镇理端人。自觉鼻塞、鼻涕中带血,耳闷堵感,头痛,听力下降,经医院检查为鼻咽癌。于2012年9月到我诊馆就诊,服用本发明人的抗肿瘤保健茶十天,各症状减轻。继续服用半年,各症状消失,能正常工作。
7.胃癌,许x,女,56岁,广西桂平市木乐镇四合村人,患者出现上腹部饱胀感,进食时加重,有厌食感,同时出现黑便,经检查为胃肿瘤。于2013年8月到我诊馆就诊,服用本发明人抗肿瘤保健茶14天,以上各症状减轻,后继续服用抗肿瘤保健茶10个月,各症状消失,复检肿瘤明显变小。
8.直肠肿瘤,林x,女,45岁,广西桂平木圭镇金垌村人,自发觉大便习惯改变,早上次数增多,经常出现粘液脓血便,里急后重,经医院检查为直肠肿瘤,于2015年12月到我诊馆就诊,服用本发明人的抗肿瘤保健茶,服用十天各症状减轻,后嘱患者继续服用6个月,各症状消失,复检肿瘤缩小。
9.脑肿癌,吴x,男45岁,广西桂平马皮乡人,经常出现头痛、恶心、呕吐、偏身麻木、四肢冰冷、意志力消沉、怕见人,有时视力模湖,医院诊断为脑肿瘤,经多方处理效果不佳,于2016年元月,到我诊馆就诊,服用本发明人的抗肿瘤保健茶,服用三天,以上各症状减轻,嘱继续服用5个月,各症状消失,能正常上班,复检肿瘤缩小。
10.肺肿瘤,江x,男,65岁,广西桂平市马皮乡人,发热、胸痛、咳血二十五天,检查为肺肿瘤,经多家医院治疗无效,于2015年4月,患者停用其他一切药物,服用本发明人的抗肿瘤保健三天,各症状减轻,继续服用4个月各症状消失。
Claims (7)
1.一种抗肿瘤的保健制剂,其特征在于:其原料组成和重量份数为:富硒茶15~30、仙鹤草10~15、绞股蓝5~10、灵芝3~8、西洋参3~5、意苡仁15~25、制茯苓10~20、白术5~10、黄芪10~20、淫羊藿5~10、银杏叶5~10、姜黄3~8、甘草4~8。
2.根据权利要求1所述的抗肿瘤的保健制剂,其特征在于:加入符合卫生标准的辅料或溶液,制成保健制剂的固体制剂或液体制剂;所述的固体制剂是胶囊剂、片剂、丸剂或颗粒剂;所述的液体制剂是口服液或糖浆剂。
3.根据权利要求1所述的抗肿瘤的保健制剂,其特征在于:该保健制剂是袋泡茶。
4.根据权利要求1或2所述的抗肿瘤的保健制剂的制备方法,其特征在于:制备过程包括以下步骤:
1)将灵芝原料用清水洗净,切成1~3cm小块,100~120℃热风烘干至水分低于5%,用超微粉碎机粉碎,过500目筛,得到灵芝超微粉,包装备用;
2)将西洋参切成1~3cm小块,100~120℃热风烘干至水分低于5%,用超微粉碎机粉碎,过500目筛,得到西洋参超微粉,包装备用;
3)将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草干燥,分别打成细粉,备用;
4)接种后三年的茯苓采挖,洗净,用麦草铺在底部,将茯苓逐层铺叠,最上盖以厚麻袋,使其发汗,析出水分,取出,将水珠擦去,摊放阴凉处,待表面干燥后再发汗,如此反复3-4次至表面皱缩,皮色变为褐色,再置阴凉处晾至半干,分部切制,阴干;使用前将茯苓浸泡,洗净除去杂质,切片,用水蒸气蒸30分钟, 然后用武火将细沙炒热,再将茯苓片倒入,炒成微黄色时,取出,筛去细沙,摊凉,打成超微粉,得到制茯苓,备用。
5.根据权利要求4所述的抗肿瘤的保健制剂,其特征在于:将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草细粉合并,加8倍量体积浓度70-90%的乙醇提取两次,每次2h,滤过,合并滤液,放置过夜,回收乙醇并浓缩至60℃相对密度为1.12-1.15的浓液,得乙醇提取液;再将药渣加入5倍重量水,煎煮2次,每次0.5小时,滤过,合并煎液,浓缩至60℃相对密度为1.05,合并乙醇提取液,回收乙醇并浓缩至60℃相对密度为1.12-1.15,与上述醇提浓缩液合并,继续浓缩至60℃相对密度为1.25-1.30的稠膏,减压干燥,粉碎成细粉,加入灵芝超微粉、西洋参超微粉、茯苓超微粉及辅料,制成片剂、颗粒剂、胶囊和丸剂,即得固体制剂。
6.根据权利要求4所述的抗肿瘤的保健制剂,其特征在于:将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草细粉合并,加8倍量体积浓度70-90%的乙醇提取二次,每次2h,滤过,合并滤液,放置过夜,回收乙醇并浓缩至60℃相对密度为1.12-1.15的浓液,得乙醇提取液;再将药渣及灵芝超微粉、西洋参超微粉、茯苓超微粉加入10倍量水,煎煮三次,每次0.5小时,滤过,合并煎液,浓缩至60℃相对密度为1.05,调节含醇量至70%,冷藏过夜,回收乙醇并浓缩至60℃相对密度为1.12-1.15,与上述醇提浓缩液合并,再加适量糖浆和水,包装,高温灭菌,即得液体制剂。
7.根据权利要求1或3所述的抗肿瘤的保健制剂,其特征在于:将富硒茶、仙鹤草、绞股蓝、意苡仁、白术、黄芪、淫羊藿、银杏叶、姜黄和甘草细粉合并,再将灵芝超微粉、西洋参超微粉、茯苓超微粉加入,包装,微波灭菌,即得袋泡茶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610745179.2A CN106215118A (zh) | 2016-08-29 | 2016-08-29 | 抗肿瘤的保健制剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610745179.2A CN106215118A (zh) | 2016-08-29 | 2016-08-29 | 抗肿瘤的保健制剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106215118A true CN106215118A (zh) | 2016-12-14 |
Family
ID=57555741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610745179.2A Pending CN106215118A (zh) | 2016-08-29 | 2016-08-29 | 抗肿瘤的保健制剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106215118A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108354184A (zh) * | 2017-12-28 | 2018-08-03 | 防城港圣保堂制药有限公司 | 一种用于癌症食疗的人参芡实粉及其制备方法 |
| CN111888420A (zh) * | 2020-08-17 | 2020-11-06 | 江西优培文化传媒有限公司 | 一种抗肿瘤的含硒组合物及其制备方法 |
| CN113244372A (zh) * | 2021-04-22 | 2021-08-13 | 建昌帮药业有限公司 | 一种增强免疫力的组合物及其制备工艺与应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247479A (zh) * | 2011-06-03 | 2011-11-23 | 广西壮族自治区民族医药研究院 | 一种抗肿瘤壮药及其制备方法 |
| CN104547810A (zh) * | 2014-12-30 | 2015-04-29 | 范士怀 | 一种治疗肺癌的中药制剂 |
-
2016
- 2016-08-29 CN CN201610745179.2A patent/CN106215118A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102247479A (zh) * | 2011-06-03 | 2011-11-23 | 广西壮族自治区民族医药研究院 | 一种抗肿瘤壮药及其制备方法 |
| CN104547810A (zh) * | 2014-12-30 | 2015-04-29 | 范士怀 | 一种治疗肺癌的中药制剂 |
Non-Patent Citations (1)
| Title |
|---|
| 杜琴等: "补益中药抗肝癌作用研究概况", 《中药材》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108354184A (zh) * | 2017-12-28 | 2018-08-03 | 防城港圣保堂制药有限公司 | 一种用于癌症食疗的人参芡实粉及其制备方法 |
| CN111888420A (zh) * | 2020-08-17 | 2020-11-06 | 江西优培文化传媒有限公司 | 一种抗肿瘤的含硒组合物及其制备方法 |
| CN113244372A (zh) * | 2021-04-22 | 2021-08-13 | 建昌帮药业有限公司 | 一种增强免疫力的组合物及其制备工艺与应用 |
| CN113244372B (zh) * | 2021-04-22 | 2023-04-28 | 建昌帮药业有限公司 | 一种增强免疫力的组合物及其制备工艺与应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102988638B (zh) | 一种青钱柳叶降脂降糖保健茶及其制备方法 | |
| CN103719498B (zh) | 一种提高免疫力的黄精保健茶及其制备方法 | |
| CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
| CN103719492A (zh) | 一种绞股蓝护肝养肝保健茶及其制备方法 | |
| CN103520694A (zh) | 治疗慢性阻塞性肺病稳定期的中药组合物及其制备方法 | |
| CN104305205B (zh) | 一种提高免疫力的菟丝子口服液及其制备方法 | |
| CN103301413A (zh) | 一种治疗高血脂合并高血糖症的中药组合物 | |
| CN103301267B (zh) | 一种治疗高血压和/或动脉粥样硬化的中药组合物及应用 | |
| CN102247479B (zh) | 一种抗肿瘤壮药及其制备方法 | |
| CN104223297B (zh) | 一种延缓衰老的五味子保健口服液及其制备方法 | |
| CN103656121A (zh) | 提高免疫力的中药组合物及制备方法 | |
| CN106215118A (zh) | 抗肿瘤的保健制剂及其制备方法 | |
| CN102178781B (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法 | |
| CN104043077A (zh) | 一种用于补气血的中药组合物 | |
| CN102908470A (zh) | 一种壮阳的中药制剂及其制备方法 | |
| CN114712470B (zh) | 一种治疗男士肾亏的药物及其制备方法 | |
| CN104258224A (zh) | 一种治疗肺肾阴虚型慢性支气管炎的五味子口服液及其制备方法 | |
| CN106166276A (zh) | 治疗湿疹的中药组合物 | |
| CN104922595A (zh) | 一种用于带状疱疹的中药制剂及其制备方法 | |
| CN106039075A (zh) | 一种治疗肺胃蕴热型慢性咽炎的中药组合物及方法 | |
| CN104771558A (zh) | 治疗肾炎的中药组合物及制备方法 | |
| CN104707003B (zh) | 治疗高血压、高血脂的中药胶囊 | |
| CN103520403B (zh) | 一种治疗ⅱ型糖尿病的中药 | |
| CN104306496A (zh) | 风湿性心脏病补益心脾制剂及制备方法 | |
| CN104800573A (zh) | 一种治疗肝癌的中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161214 |
|
| RJ01 | Rejection of invention patent application after publication |